港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

撥康視雲-B

4.520

+0.1904.39%

成交量：31.90萬

成交額：141.13萬

市值：38.19億

市盈率：-2.79

高：4.560

開：4.330

低：4.270

收：4.330

52周最高：9.740

52周最低：3.940

股本：8.45億

香港流通股本：8.45億

量比：4.81

換手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-1.622

淨資產收益率：--

總資產收益率：-44.38%

市淨率：-1.49

市盈率(LYR):-2.79

市銷率: 47.96

資料載入中...

總覽公司新聞資訊公告

手握2款3期新藥，眼科明星Biotech港股上市

动脉新医药

撥康視雲正式上市百惠擔任聯席賬簿管理人及聯席牽頭經辦人

中宏网官微

新股首日 | 撥康視雲-B跌超16%，公司為臨牀階段眼科生物科技公司

異動解讀 | 撥康視雲-B首日掛牌大跌7.43%，IPO超額認購熱情難挽股價下跌

異動解讀 | 撥康視雲-B上市首日盤中大跌7.43%，較招股價跌超13%

港股公告掘金 | 小鵬汽車6月智能電動汽車交付量同比增長224% 撥康視雲明日上市

撥康視雲-B(02592)公開發售獲78.78倍認購全球發售淨籌約5.22億港元

老虎暗盤｜撥康視雲漲近9%，中籤一手賺超450港元，市值92.28億港元

老虎资讯综合

撥康視雲四戰港交所：三年虧損超20億元，創始人千萬年薪碾壓同行

撥康視雲四戰港交所：三年虧損超20億元，創始人千萬年薪碾壓同行

【港股IPO動態：今日週六福、聖貝拉、穎通控股上市】今日週六福(6168.HK)、聖貝拉(2508.HK)、穎通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、撥康視雲-B (2592.HK)申購。

音頻 | 格隆匯6.25盤前要點—港A美股你需要關注的大事都在這

撥康視雲引入基石投資者助力眼科創新藥研發

撥康視雲-B(02592)今起招股引入富策控股及Reynold Lemkins作為基石

【撥康視雲-B(02592.HK)今起招股引入富策控股及Reynold Lemkins作為基石】智通財經APP訊，撥康

【新股IPO】撥康視雲-B(02592)今日起招股入場費5,100.94港元

撥康視雲港股IPO每股定價10.1港元預計7月3日上市

《新股》撥康視雲(02592.HK)今起招股入場費5,100.9元

阿斯达克财经

新股招股｜撥康視雲-B今起招股，一手入場費約5100.94港元

老虎资讯综合

撥康視雲港股IPO每股定價10.1港元預計7月3日上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02592/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"撥康視雲-B","latestPrice":4.52,"timestamp":1763436682372,"preClose":4.33,"halted":0,"volume":319000,"delay":0,"floatShares":844999999,"shares":844999999,"eps":-1.6215638244099693,"marketStatus":"交易中","change":0.19,"latestTime":"11-18 11:32:59","open":4.33,"high":4.56,"low":4.27,"amount":1411285,"amplitude":0.066975,"askPrice":4.56,"askSize":2000,"bidPrice":4.5,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-1.309817644542945,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1763438400000},"marketStatusCode":2,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":4.33,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":4.805467,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":844999999,"roa":"-44.38%","roe":"--","lyrEps":-1.621564,"volumeRatio":4.805467,"shares":844999999,"dividePrice":0,"high":4.56,"amplitude":0.066975,"preClose":4.33,"low":4.27,"week52Low":3.94,"pbRate":"-1.49","psRate":"47.96","week52High":9.74,"institutionHeld":0,"latestPrice":4.52,"committee":0.384615,"eps":-1.6215638244099693,"divideRate":0,"volume":319000,"delay":0,"ttmEps":-1.309817644542945,"open":4.33,"prevYearClose":10.1,"prevWeekClose":4.46,"prevMonthClose":4.71,"prevQuarterClose":4.51,"fiveDayClose":4.6,"twentyDayClose":4.84,"sixtyDayClose":5.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2025-11-14","current":-3.306575,"percent":0.365591,"low":-13.478827,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"high":-5.348116,"avg":-8.53714,"sd":3.119566,"marketCap":3741462218},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218}],"updateTime":1763416721677},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548896683","title":"手握2款3期新藥，眼科明星Biotech港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548896683","media":"动脉新医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548896683?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 19:05","pubTimestamp":1751540741,"startTime":"0","endTime":"0","summary":"7月3日，“眼科创新药新锐”Cloudbreak Pharma Inc.拨康视云在港交所正式上市。其全球治疗药物市场规模预计将于2027年达到2.73亿美元、2032年达到25.29亿美元，复合年增长率为56.0%。因此，CBT-001有望成为治疗翼状胬肉的全球首创药物，享有先发优势。弗若斯特沙利文报告显示，全球治疗青少年近视药物的市场规模由2018年的7230万美元增加至2022年的8400万美元，复合年增长率为3.8%。2022年，全球睑板腺功能异常相关的干眼症患者人数将达到9.232亿人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","07226","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2548708798","title":"撥康視雲正式上市 百惠擔任聯席賬簿管理人及聯席牽頭經辦人","url":"https://stock-news.laohu8.com/highlight/detail?id=2548708798","media":"中宏网官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548708798?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 16:27","pubTimestamp":1751531220,"startTime":"0","endTime":"0","summary":"，正式登陆香港联交所主板，每股定价为10.10港元，录得近78倍超额认购，百惠金控团队担任联席账簿管理人及联席牵头经办人。　　作为本次 IPO 项目的联席账簿管理人及联席牵头经办人，百惠金控团队充分调动自身广泛的市场资源，为拨康视云提供全周期上市解决方案。同时，旗下的百惠资本持有第六类牌照，并且拥有保荐人资格。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-03/doc-infeevpi3404944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02592"],"gpt_icon":1},{"id":"2548502842","title":"新股首日 | 撥康視雲-B跌超16%，公司為臨牀階段眼科生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2548502842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548502842?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 09:38","pubTimestamp":1751506715,"startTime":"0","endTime":"0","summary":"7月3日，拨康视云-B首日盘初跌超16%，成交额8232万港元。公开资料显示，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。集团已经建立一个由候选药物组成的创新管线，覆盖眼睛前部和后部的主要疾病，其中有四款处于临床阶段的候选药物及四款处于临床前阶段的候选药物，管线中的所有候选药物均为自主研发。核心产品CBT-001适用于治疗翼状胬肉，集团分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313367.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"1191258223","title":"異動解讀 | 撥康視雲-B首日掛牌大跌7.43%，IPO超額認購熱情難挽股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191258223","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191258223?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 09:32","pubTimestamp":1751506361,"startTime":"0","endTime":"0","summary":"临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"1187279368","title":"異動解讀 | 撥康視雲-B上市首日盤中大跌7.43%，較招股價跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187279368","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187279368?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 09:32","pubTimestamp":1751506350,"startTime":"0","endTime":"0","summary":"拨康视云-B今日在港交所主板挂牌上市，盘中大跌7.43%，股价跌至9.35港元，较10.1港元的招股价下跌超过13%，引发市场关注。拨康视云-B是一家临床阶段眼科生物科技公司，致力于开发新型及差异化疗法。然而，该股今日开盘即表现疲软，开盘价为9.5港元，较招股价低5.94%。分析人士指出，尽管公司IPO获得较高认购倍数，但上市首日股价表现不佳，可能反映了投资者对生物科技公司长期盈利能力的担忧，以及当前市场对新股的谨慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"2548381566","title":"港股公告掘金 | 小鵬汽車6月智能電動汽車交付量同比增長224% 撥康視雲明日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548381566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548381566?lang=zh_tw&edition=fundamental","pubTime":"2025-07-02 22:58","pubTimestamp":1751468287,"startTime":"0","endTime":"0","summary":"【重大事项】拨康视云-B(02592)公开发售获78.78倍认购 全球发售净筹约5.22亿港元首钢朗泽(02553)因民事诉讼将延迟全球发售及上市德林控股(01709)拟携手Asseto在亚洲市场共同探索并开发RWA的代币化解决方案万国数据-SW(09698)：C-REIT的首次公开发售(IPO)的最终发售价为每份额3.00元宜明昂科-B(01541)：IMM2510/AXN-2510获美国FDA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1a5d46f67449d510f0b2e6d4ffc20b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4099","BK1587","HSCEI","BK1119","YANG","07226","BK4555","BK1610","02603","HSTECH","BK1575","02592","09868","BK1539","01045","BK1137","BK4505","BK1108","EVS.SI","BK1588","BK4526","LU0593848301.USD","BK4551","BK4614","XPEV"],"gpt_icon":0},{"id":"2548852894","title":"撥康視雲-B(02592)公開發售獲78.78倍認購 全球發售淨籌約5.22億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548852894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548852894?lang=zh_tw&edition=fundamental","pubTime":"2025-07-02 20:07","pubTimestamp":1751458071,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)公布配发结果，公司全球发售6058.2万股股份，香港公开发售占20%，国际发售占80%。最终发售价为每股10.1港元，全球发售净筹约5.22亿港元。每手500股，预期股份将于 2025年7月3日(星期四)上午九时正(香港时间)在联交所开始买卖。其中，香港公开发售获78.78倍认购，国际发售获0.89倍认购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"1142745540","title":"老虎暗盤｜撥康視雲漲近9%，中籤一手賺超450港元，市值92.28億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142745540","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142745540?lang=zh_tw&edition=fundamental","pubTime":"2025-07-02 16:33","pubTimestamp":1751445224,"startTime":"0","endTime":"0","summary":"周三，拨康视云开启暗盘涨近9%，中签一手赚超450港元，市值92.28亿港元公司介绍：集团是一间临床阶段眼科生物科技公司，致力于开发各种疗法。集团已订立基石投资协议，据此，在若干条件规限下，基石投资者已同意按发售价认购以总额2280万美元可认购的发售股份数目。按每股发售股份发售价10.10港元计算，估计集团将自全球发售收取所得款项净额约5.222亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"105923918965a0539d0eff1a540dbfb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2548005855","title":"撥康視雲四戰港交所：三年虧損超20億元，創始人千萬年薪碾壓同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2548005855","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548005855?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 19:11","pubTimestamp":1751368300,"startTime":"0","endTime":"0","summary":"此前，拨康视云先后于2023年11月、2024年5月、2024年12月三次向港交所递交上市申请，均以失败告终。根据许可协议，拨康视云获得了1000万美元的首付款，预计还能获得临床开发及监管里程碑付款总计不超过9100万美元，并有权根据销售额收取分级专利权费付款。据招股书，倪劲松及其配偶通过间接持股及家族信托，合计持有拨康视云股份约22.18%，其中倪劲松持有约20.86%，其配偶持有约1.32%。拨康视云核心管理层的现金薪酬水平显著高于行业头部企业掌舵者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1751104966030417205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02592"],"gpt_icon":1},{"id":"2546724212","title":"撥康視雲四戰港交所：三年虧損超20億元，創始人千萬年薪碾壓同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2546724212","media":"子弹财观","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546724212?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 21:00","pubTimestamp":1751029220,"startTime":"0","endTime":"0","summary":"此前，拨康视云先后于2023年11月、2024年5月、2024年12月三次向港交所递交上市申请，均以失败告终。根据许可协议，拨康视云获得了1000万美元的首付款，预计还能获得临床开发及监管里程碑付款总计不超过9100万美元，并有权根据销售额收取分级专利权费付款。据招股书，倪劲松及其配偶通过间接持股及家族信托，合计持有拨康视云股份约22.18%，其中倪劲松持有约20.86%，其配偶持有约1.32%。拨康视云核心管理层的现金薪酬水平显著高于行业头部企业掌舵者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210300a4c14da4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210300a4c14da4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2546214982","title":"【港股IPO動態：今日週六福、聖貝拉、穎通控股上市】今日週六福(6168.HK)、聖貝拉(2508.HK)、穎通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、撥康視雲-B (2592.HK)申購。","url":"https://stock-news.laohu8.com/highlight/detail?id=2546214982","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546214982?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 06:35","pubTimestamp":1750890915,"startTime":"0","endTime":"0","summary":"今日周六福(6168.HK)、圣贝拉(2508.HK)、颖通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、拨康视云-B (2592.HK)申购。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9835176c868bcdb544d7d548fe3d02fe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/26063551311402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0359201612.USD","BK4505","BK4503","603345","BK4614","06168","YANG","LU1688375341.USD","BK4077","BK4535","BK4551","BK4563","02076","BK4539","02592","BK4526","BK4588","IE00B29SXG58.USD","BZ","BK4509","02508","BK4585","LU1997245177.USD","BK1095","LU1023057109.AUD","02648","BK0201","BK0238","06883","LU0359202008.SGD","LU2039709279.SGD","LU1997245094.SGD","BK1148","HSTECH"],"gpt_icon":0},{"id":"2546519142","title":"音頻 | 格隆匯6.25盤前要點—港A美股你需要關注的大事都在這","url":"https://stock-news.laohu8.com/highlight/detail?id=2546519142","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546519142?lang=zh_tw&edition=fundamental","pubTime":"2025-06-25 07:38","pubTimestamp":1750808328,"startTime":"0","endTime":"0","summary":"以伊停火生效，美股三大指数均涨超1%，中概指数涨3.31%，美油期货大跌6%；鲍威尔称或可提前降息；欧盟拟采取更多反制措施以对美施压；提及中长期资金入市、提高居民财产性收入，央行等六部门发文；柠檬价格暴涨300%...","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2380950","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1502","BK1541","BK1151","BK1604","BK1587","02592","02618"],"gpt_icon":0},{"id":"2545470372","title":"撥康視雲引入基石投資者 助力眼科創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2545470372","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545470372?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 14:35","pubTimestamp":1750746902,"startTime":"0","endTime":"0","summary":"眼科创新药研发商拨康视云近日宣布，在本次发行中成功引入两名基石投资者，累计认购金额达2280万美元（约1.79亿港元）。其中，知名天使投资人龚虹嘉全资持有的富策控股认购2000万美元，瑞凯集团认购280万美元。拨康视云专注于小分子多激酶抑制剂和抗体-小分子协作偶联技术平台的开发，覆盖眼表、青光眼及眼底疾病领域。此次融资将加速其创新药物的研发进程，为眼科疾病治疗提供更多解决方案。基石投资者的加入，进一步彰显市场对其技术实力和发展前景的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624143918978c634f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624143918978c634f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02592","BK1161","06978"],"gpt_icon":0},{"id":"2545653424","title":"撥康視雲-B(02592)今起招股 引入富策控股及Reynold Lemkins作為基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2545653424","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545653424?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 09:14","pubTimestamp":1750727668,"startTime":"0","endTime":"0","summary":"集团拥有两款核心产品，均为自主开发。核心产品CBT-001适用于治疗翼状胬肉，集团分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。自成立以来，公司尚未获利，并且每年均取得经营亏损。于截至2022年、2023年及2024年12月31日止年度，我们的经营亏损分别为2300万美元、3720万美元及3660万美元。按发售价10.10港元计算，基石投资者将予认购的发售股份总数将为1772万股发售股份。基石投资者包括富策控股有限公司及The Reynold Lemkins Group  Limited。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"2545424632","title":"【撥康視雲-B(02592.HK)今起招股 引入富策控股及Reynold Lemkins作為基石】智通財經APP訊，撥康","url":"https://stock-news.laohu8.com/highlight/detail?id=2545424632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545424632?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 09:14","pubTimestamp":1750727668,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"2545397421","title":"【新股IPO】撥康視雲-B(02592)今日起招股 入場費5,100.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545397421","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545397421?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:42","pubTimestamp":1750725757,"startTime":"0","endTime":"0","summary":"金吾财讯 | 拨康视云-B(02592)今日起招股，拟发行6058.2万股，其中90%)为国际发售，10%)为香港发售。每股招股价为10.1港元，每手500股，入场费5,100.94港元，建银国际、华泰国际为联席保荐人。股份预期将于7月3日挂牌上市。此次集资净额预期为5.22亿港元，公司拟将其中约62.4%将用于拨付核心产品CBT-001的持续临床研发活动，以及注册备案及获批后研究所需资金；约27.6%将用于拨付持续临床研发活动，以及核心产品CBT-009的注册备案的所需资金；约5.5%将用于拨付生产设施及商业化活动所需资金；及约4.5%将用作营运资金及其他一般企业用途。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/Mjg2N2JhODhiZjBhODVmMjEwMzAwNTY4MTI5NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/Mjg2N2JhODhiZjBhODVmMjEwMzAwNTY4MTI5NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960968","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2545421783","title":"撥康視雲港股IPO每股定價10.1港元 預計7月3日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2545421783","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545421783?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:42","pubTimestamp":1750725747,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2QAI56F0519QIKK.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2QAI56F0519QIKK.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0},{"id":"2545421959","title":"《新股》撥康視雲(02592.HK)今起招股 入場費5,100.9元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545421959","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545421959?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:25","pubTimestamp":1750724700,"startTime":"0","endTime":"0","summary":"临床阶段眼科生物科技公司拨康视云-B公布在港首次公开发售详情，计划全球发售6,058.2万股，当中国际配售部分占90%，香港公开发售占10%，发售价为每股10.1元，预料集资近6.12亿元。每手买卖单位500股，入场费约5,100.94元。招股期由今日起至周五止，预计会于7月3日挂牌上市。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250624083337109_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250624083337109_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1448680/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02592"],"gpt_icon":0},{"id":"1144400905","title":"新股招股｜撥康視雲-B今起招股，一手入場費約5100.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144400905","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144400905?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:23","pubTimestamp":1750724632,"startTime":"0","endTime":"0","summary":"申购阶梯：每手500股，入场费5100.94港元。乙组门槛为50万股，申购所需资金约510.09万港元。按发售价10.10港元计算，基石投资者将予认购的发售股份总数将为1772万股发售股份。基石投资者包括富策控股有限公司及The Reynold Lemkins Group  Limited。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜拨康视云-B今起招股，一手入场费约5100.94港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2545429002","title":"撥康視雲港股IPO每股定價10.1港元 預計7月3日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2545429002","media":"观点机构","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545429002?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:22","pubTimestamp":1750724575,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K2Q9ECNC0519D45U.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K2Q9ECNC0519D45U.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02592"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":82,"code":"91000000","status":"200"}]}}